GlassScriptPhysician profile
Dron P Bhandari
NPI 1841562774
$7,516.00
in general payments reported to CMS, 2019-2025
28 companies · $994 in 2025
The $994 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $547 · 2021: $2,759 · 2022: $927 · 2023: $787 · 2024: $796 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536 · Education: $41.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.20 |
| Education | $41.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,455.96 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $1,280.55 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $752.35 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Glaxosmithkline, LLC. | $352.71 | 2021-2025 | Benlysta, Jesduvroq |
| Travere Therapeutics, INC. | $305.04 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $304.18 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $301.38 | 2020-2025 | Acthar |
| Vifor Pharma, INC. | $252.54 | 2019-2025 | Veltassa |
| Mallinckrodt Enterprises LLC | $184.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $151.43 | 2019-2025 | |
| Fresenius USA Marketing, INC. | $121.29 | 2022-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $114.23 | 2024-2025 | Wegovy, Ozempic |
| Opko Pharmaceuticals, LLC | $108.31 | 2019-2023 | Rayaldee |
| Akebia Therapeutics INC | $104.87 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $95.54 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $94.73 | 2020-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.64 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $92.43 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $68.74 | 2019-2023 | Ultomiris |
| Ardelyx, INC. | $57.15 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $42.47 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.43 | 2019 | |
| Ani Pharmaceuticals, INC. | $34.19 | 2022-2023 | Purified Cortrophin Gel |
| Lilly USA, LLC | $32.58 | 2023-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $27.57 | 2025 | Tarpeyo |
| Organogenesis INC. | $17.60 | 2025 | Apligraf |
| Alnylam Pharmaceuticals INC. | $16.20 | 2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dron Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.